Clinical Trial

A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the impact of HRS9531 on major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease. This study adopts an event-driven design and ends when the target number of the primary endpoint event is reached.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-06
Trial Details
NCT Number NCT07551492
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Atherosclerotic Cardiovascular Disease
Enrollment 9,262 participants
Start Date 2026-05-29
Primary Completion 2031-05 (estimated)
Study Completion 2031-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-05